Is response rate relevant to the phase II trial design of targeted agents?
Dowlati
Afshin
A
Fu
Pingfu
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D012107:Research Design
D014408:Biomarkers, Tumor